Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

May Shawi

Showing results (41-50 of 50) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 50 results.
Drug Safety|October 31, 2023
Long-Term Safety of Guselkumab in Patients with Psoriatic Disease: An Integrated Analysis of Eleven Phase II/III Clinical Studies in Psoriasis and Psoriatic ArthritisBruce Strober, Laura C Coates, Mark G Lebwohl, et al.
BMJ Open|April 7, 2016
Biologic Treatment Registry Across Canada (BioTRAC): a multicentre, prospective, observational study of patients treated with infliximab for ankylosing spondylitisProton Rahman, Denis Choquette, William G Bensen, et al.
RMD Open|March 17, 2022
Sustained and improved guselkumab response in patients with active psoriatic arthritis regardless of baseline demographic and disease characteristics: pooled results through week 52 of two phase III, randomised, placebo-controlled studiesChristopher T Ritchlin, Philip J Mease, Wolf-Henning Boehncke, et al.
Annals of the Rheumatic Diseases|April 29, 2022
Correspondence on 'No efficacy of anti-IL-23 therapy for axial spondyloarthritis in randomised controlled trials but in post-hoc analyses of psoriatic arthritis-related 'physician-reported spondylitis'?'Dafna D Gladman, Philip J Mease, Paul Bird, et al.
Rheumatology (Oxford, England)|April 6, 2021
Resolution of enthesitis by guselkumab and relationships to disease burden: 1-year results of two phase 3 psoriatic arthritis studiesDennis McGonagle, Iain B McInnes, Atul Deodhar, et al.
Trials|September 5, 2022
Efficacy and safety of guselkumab in biologic-naïve patients with active axial psoriatic arthritis: study protocol for STAR, a phase 4, randomized, double-blinded, placebo-controlled trialDafna D Gladman, Philip J Mease, Paul Bird, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|January 22, 2024
Modulation of Interleukin-23 Signaling With Guselkumab in Biologic-Naive Patients Versus Tumor Necrosis Factor Inhibitor-Inadequate Responders With Active Psoriatic ArthritisStefan Siebert, Laura C Coates, Georg Schett, et al.
The Journal of Rheumatology|May 2, 2021
Pooled Safety Results Through 1 Year of 2 Phase III Trials of Guselkumab in Patients With Psoriatic ArthritisProton Rahman, Christopher T Ritchlin, Philip S Helliwell, et al.
The Lancet. Rheumatology|January 30, 2024
Efficacy of guselkumab on axial involvement in patients with active psoriatic arthritis and sacroiliitis: a post-hoc analysis of the phase 3 DISCOVER-1 and DISCOVER-2 studiesPhilip J Mease, Philip S Helliwell, Dafna D Gladman, et al.
RMD Open|February 11, 2021
Guselkumab, an inhibitor of the IL-23p19 subunit, provides sustained improvement in signs and symptoms of active psoriatic arthritis: 1 year results of a phase III randomised study of patients who were biologic-naïve or TNFα inhibitor-experiencedChristopher T Ritchlin, Philip S Helliwell, Wolf-Henning Boehncke, et al.
Pageof 5

Showing results (41-50 of 50) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 50 results.
Drug Safety|October 31, 2023
Long-Term Safety of Guselkumab in Patients with Psoriatic Disease: An Integrated Analysis of Eleven Phase II/III Clinical Studies in Psoriasis and Psoriatic ArthritisBruce Strober, Laura C Coates, Mark G Lebwohl, et al.
BMJ Open|April 7, 2016
Biologic Treatment Registry Across Canada (BioTRAC): a multicentre, prospective, observational study of patients treated with infliximab for ankylosing spondylitisProton Rahman, Denis Choquette, William G Bensen, et al.
RMD Open|March 17, 2022
Sustained and improved guselkumab response in patients with active psoriatic arthritis regardless of baseline demographic and disease characteristics: pooled results through week 52 of two phase III, randomised, placebo-controlled studiesChristopher T Ritchlin, Philip J Mease, Wolf-Henning Boehncke, et al.
Annals of the Rheumatic Diseases|April 29, 2022
Correspondence on 'No efficacy of anti-IL-23 therapy for axial spondyloarthritis in randomised controlled trials but in post-hoc analyses of psoriatic arthritis-related 'physician-reported spondylitis'?'Dafna D Gladman, Philip J Mease, Paul Bird, et al.
Rheumatology (Oxford, England)|April 6, 2021
Resolution of enthesitis by guselkumab and relationships to disease burden: 1-year results of two phase 3 psoriatic arthritis studiesDennis McGonagle, Iain B McInnes, Atul Deodhar, et al.
Trials|September 5, 2022
Efficacy and safety of guselkumab in biologic-naïve patients with active axial psoriatic arthritis: study protocol for STAR, a phase 4, randomized, double-blinded, placebo-controlled trialDafna D Gladman, Philip J Mease, Paul Bird, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|January 22, 2024
Modulation of Interleukin-23 Signaling With Guselkumab in Biologic-Naive Patients Versus Tumor Necrosis Factor Inhibitor-Inadequate Responders With Active Psoriatic ArthritisStefan Siebert, Laura C Coates, Georg Schett, et al.
The Journal of Rheumatology|May 2, 2021
Pooled Safety Results Through 1 Year of 2 Phase III Trials of Guselkumab in Patients With Psoriatic ArthritisProton Rahman, Christopher T Ritchlin, Philip S Helliwell, et al.
The Lancet. Rheumatology|January 30, 2024
Efficacy of guselkumab on axial involvement in patients with active psoriatic arthritis and sacroiliitis: a post-hoc analysis of the phase 3 DISCOVER-1 and DISCOVER-2 studiesPhilip J Mease, Philip S Helliwell, Dafna D Gladman, et al.
RMD Open|February 11, 2021
Guselkumab, an inhibitor of the IL-23p19 subunit, provides sustained improvement in signs and symptoms of active psoriatic arthritis: 1 year results of a phase III randomised study of patients who were biologic-naïve or TNFα inhibitor-experiencedChristopher T Ritchlin, Philip S Helliwell, Wolf-Henning Boehncke, et al.
Pageof 5